

Pressemitteilung

Tubulis closes a series B financing in the amount of 60 million and moves into IZB in June 2022

Start-up aims to accelerate its ADC pipeline and expand its range of platform technologies

Munich/Martinsried, May 3, 2022 – Tubulis today announced the successful completion of a €60 million (USD \$63 million) Series B financing led by Andera Partners with participation from new investors Evotec and Fund+. All existing investors also participated in the round, including Bayern Kapital (with Wachstumsfonds Bayern 2), BioMedPartners, coparion, High-Tech Gründerfonds (HTGF), OCCIDENT and Seventure Partners. The new capital will be used to advance Tubulis' proprietary pipeline of uniquely assembled antibody drug conjugates (ADCs), towards clinical evaluation as well as introduce programs addressing a range of solid tumor indications. The proceeds will enable the company to deliver the true therapeutic potential of ADCs through further innovation of novel payload classes and identification of new cancer targets.

“This funding emphasizes that Tubulis is uniquely positioned to consolidate the findings of the last 20 years in the ADC field and translate this understanding into meaningful therapeutic benefits for patients. We have reached an important inflection point in the development of our platform technologies as well as our pipeline of highly novel protein-drug conjugates and we are now focused on unlocking new avenues in the treatment of solid tumors bringing safe and effective ADCs to patients,” said Dominik Schumacher, PhD, CEO and co-founder of Tubulis. “With this capital in place, we will execute on our growth strategy, including important focus areas for our pipeline and for how we can apply our proprietary technologies, biologic insights and new mechanisms of action to enable the true therapeutic value inherent in targeted therapeutics.”

In conjunction with the round, Sofia Ioannidou, PhD, Partner at Andera Partners, Thomas Hanke, PhD, EVP, Head of Academic Partnerships at Evotec as well as Jan Van den Bossche, Partner at Fund+ will join Tubulis' Board of Directors consisting of Sebastian Pünzeler, PhD, Principal at coparion, Dominik Schumacher, PhD, CEO of Tubulis and Christian Grøndahl, MD, DVM, PhD, MBA, the Chairman of the Board. In addition, Valentin Piëch, PhD, Partner at BioMedPartners will take over the board seat from Michael Wacker, PhD, General Partner at BioMedPartners. Biographies for all board members can be found [here](#).

“With its unique toolkit of proprietary technologies and its pipeline of differentiated ADC candidates, Tubulis holds a compelling position in the ADC field,” stated Andera Partners' Sofia Ioannidou, PhD. “We look forward to supporting this talented team in bringing innovative ADCs to patients and are confident that Tubulis has the potential to become a leader in the next era of ADC drug development.”

Tubulis' capability of creating a pipeline of antibody-drug conjugates is based on a diverse range of targeting molecules, novel payloads, and proprietary conjugation technologies. They enable the discovery of truly innovative ADCs that go beyond traditional payload classes and can increase antibody conjugation options via novel chemical groups leading to stable, high



drug-to-antibody ratios. Tubulis has developed superior Topoisomerase-I linker-payloads with significantly improved pharmacokinetic properties and unique conjugation chemistry enabling access to a novel payload class that has been chemically challenging for conjugation in the past.

The company's lead tumor-targeting assets build upon this technological breadth and are currently in preclinical development addressing several high unmet medical need indications. Tubulis' pipeline also includes a program for hematological tumors, which is on the path towards IND-readiness. Tubulis remains focused on pairing novel payloads with disease-specific targets to tackle the five deadliest cancer indications globally.

"We are delighted that Tubulis GmbH with its outstanding technology is moving into the Biotechnology Innovation and Start-up Center in Martinsried and that we are able to follow and support the development of this biotech start-up, which is already so successful. Of course, the close exchange with the already resident entrepreneurs will also be very useful for the management", says Dr. Peter Hanns Zobel, Managing Director IZB.

About Tubulis

Tubulis generates uniquely matched protein-drug conjugates through the combination of novel proprietary technologies and disease-specific biologic insight. Our goal is to expand the therapeutic potential of antibody-drug conjugates (ADCs) by increasing design flexibility while overcoming constraints of toxicity, efficacy, and indication. Tubulis will build new conjugates to fill its growing pipeline and will continue to collaborate with industry partners to usher in a new ADC era and deliver better outcomes for patients. Visit www.tubulis.com or follow us on [LinkedIn](#) and [Twitter](#).

Contact Tubulis

Dominik Schumacher, CEO & Co-Founder
Phone: + 49 (0) 89 2180 74233
Mail: info@tubulis.com

Media contact

Trophic Communications
Stephanie May or Laura Mittmann
Phone: + 49 (0) 171 185 5682
Email: tubulis@trophic.eu

About the Innovation and Start-up Center for Biotechnology (IZB) in Martinsried near Munich

The IZB, founded in 1995, operates the innovation and start-up centers for biotechnology in Planegg-Martinsried and Freising-Weihenstephan, which has developed into a leading biotechnology center. More than 50 biotech companies with over 700 employees are currently based on 26,000 m² of space. Here, work is being carried out on developing drugs for the most serious diseases, such as cancer, Alzheimer's and various autoimmune diseases. A key criterion for the success of the IZBs is the physical proximity to cutting-edge research on the Martinsried/Grosshadern campus and the Weihenstephan campus. The new infrastructure measures such as the Faculty Club G2B (Gateway to Biotech), the IZB Residence CAMPUS AT HOME, the Elhardt chemistry college, the two kindergartens Bio Kids and Bio Kids2, as well as the two restaurants SEVEN AND MORE and The Bowl Food Lounge are location factors that are highly valued by the company founders. Successful companies that have emerged from the

TUBULIS[®]



IZB include Corimmun (today Janssen-Cilag), Coriolis, Exosome Diagnostics (bought by Bio-Tech), ibidi, Immunic Therapeutics, Medigene, Micromet (today Amgen), MorphoSys, Octopharma or Rigontec (now MSD). More information at www.izb-online.de

Press contact and image material requests:

Susanne Simon, Head of Press and Public Relations

Fördergesellschaft IZB mbH, Innovation and Start-up Center for Biotechnology

Am Klopferspitz 19, D-82152 Planegg-Martinsried,

Phone: +49 (0)89/55 279 48-17,

E-mail: simon@izb-online.de

Website: www.izb-online.de



Photo caption (f. l.t.r.): Dr. Dominik Schumacher, CEO and Dr. Jonas Helma-Smets, CSO Tubulis GmbH